A new Cochrane review led by a team of international researchers including from U of T, has found that marketing strategies used by pharmaceutical companies such as payments… read more.
Roche announced that the FDA has approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous… read more.
Idorsia shared positive findings from two new analyses of the pivotal Phase 3 PRECISION study of aprocitentan in patients with resistant hypertension, at the American Heart Association Hypertension… read more.
Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults. Nirogacestat can only be used if… read more.
More hospitals across the U.S. are closing than opening, and urban hospitals are closing at the same rate as rural ones, according to a new study led by… read more.
Nearly one-third of people with epilepsy who were prescribed certain hormonal contraceptives also received antiseizure medications that may make those contraceptives less effective, according to a University of… read more.
Scholar Rock announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European… read more.
Biofrontera announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in… read more.
Atara Biotherapeutics, Inc. announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the FDA of the Biologics License Application (BLA) resubmission for tabelecleucel, with… read more.
If you hate needles, music might make you feel better during a cannula insertion… but it has to be the right kind of music. Although different musical interventions… read more.
Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors—commonly leading… read more.
Guardant Health announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
